Emily Pond

Researchers addressed common misconceptions regarding the diagnosis and treatment of gastroparesis.

Rates of tophus resolution increased in patients in both groups between week 24 and week 52, suggesting that the therapeutic benefits of pegloticase and MTX may extend beyond 6 months.

Pregnant patients who were enrolled in the registry between March 2020 and February 2022 were eligible for inclusion.

Participants were randomly assigned 1:1:1 to receive secukinumab 150mg, secukinumab 300mg, or adalimumab biosimilar 40mg, for 104 weeks.

The analysis included 140 patients from the SELECT-BEYOND cohort and 258 patients from the SELECT-CHOICE cohort.

Patients with ILD were randomly assigned 1:1 to receive cyclophosphamide 600mg/m2 body surface area administered every 4 weeks for a total of 6 doses or rituximab 1g administered at baseline and repeated at 2 weeks.

Researchers conducted a survey to determine whether physicians can estimate patients’ out-of-pocket expenses, based on information about drug prices and patients’ insurance plans.

Researchers addressed common misconceptions regarding the diagnosis and treatment of gastroparesis.

To assess whether states and territories adhered to these FSMB recommendations, authors obtained copies of initial license medical applications from 50 US states, the District of Columbia, Guam, the Northern Mariana Islands, and the US Virgin Islands.

The American College of Rheumatology Committee on Rheumatologic Care released an updated position statement on patient safety and site of service for biologics.